(ENSG) The Ensign - Ratings and Ratios
Nursing Care, Senior Living, Rehabilitative Services, Dialysis, Pharmacy
ENSG EPS (Earnings per Share)
ENSG Revenue
Description: ENSG The Ensign
The Ensign Group Inc (NASDAQ:ENSG) is a healthcare services provider operating in the US, focusing on skilled nursing, senior living, and rehabilitative care. The companys operations are divided into two main segments: Skilled Services, which provides a range of care services including short-term and long-term nursing care, specialty care, and standard services, and Standard Bearer, which leases post-acute care properties to healthcare operators.
With a presence in 16 states across the US, ENSG offers a broad spectrum of services, including senior living units, ancillary services such as digital x-ray and dialysis, and sub-acute services. The companys diversified service portfolio and geographic presence are key strengths, allowing it to capitalize on the growing demand for healthcare services.
From a financial perspective, ENSGs revenue growth, operating margins, and return on equity (ROE) are key performance indicators (KPIs) to monitor. With a ROE of 17.27%, the company demonstrates a reasonable return on shareholders equity. Additionally, the companys debt-to-equity ratio and interest coverage ratio are important metrics to assess its financial health and ability to service debt.
To further evaluate ENSGs investment potential, its essential to analyze its occupancy rates, average daily census, and revenue per patient day. These operational metrics can provide insights into the companys ability to maintain a stable and growing revenue stream. Furthermore, the companys ability to expand its services and increase its market share in the competitive healthcare landscape is crucial to its long-term success.
ENSG Stock Overview
| Market Cap in USD | 9,904m |
| Sub-Industry | Health Care Facilities |
| IPO / Inception | 2007-11-09 |
ENSG Stock Ratings
| Growth Rating | 68.5% |
| Fundamental | 85.1% |
| Dividend Rating | 49.7% |
| Return 12m vs S&P 500 | -8.86% |
| Analyst Rating | 4.50 of 5 |
ENSG Dividends
| Dividend Yield 12m | 0.16% |
| Yield on Cost 5y | 0.46% |
| Annual Growth 5y | 3.68% |
| Payout Consistency | 98.6% |
| Payout Ratio | 4.2% |
ENSG Growth Ratios
| Growth Correlation 3m | 73.3% |
| Growth Correlation 12m | 23.9% |
| Growth Correlation 5y | 91.6% |
| CAGR 5y | 24.89% |
| CAGR/Max DD 3y | 1.06 |
| CAGR/Mean DD 3y | 5.22 |
| Sharpe Ratio 12m | 0.85 |
| Alpha | 1.03 |
| Beta | 0.326 |
| Volatility | 27.60% |
| Current Volume | 269.2k |
| Average Volume 20d | 326.6k |
| Stop Loss | 161.2 (-3%) |
| Signal | -1.01 |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (322.8m TTM) > 0 and > 6% of Revenue (6% = 276.9m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 1.07pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 6.75% (prev 9.75%; Δ -3.00pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 462.9m > Net Income 322.8m (YES >=105%, WARN >=100%) |
| Net Debt (1.68b) to EBITDA (521.5m) ratio: 3.21 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.41 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (58.6m) change vs 12m ago 1.02% (target <= -2.0% for YES) |
| Gross Margin 18.36% (prev 14.02%; Δ 4.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 98.53% (prev 88.80%; Δ 9.73pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 51.24 (EBITDA TTM 521.5m / Interest Expense TTM 8.34m) >= 6 (WARN >= 3) |
Altman Z'' 2.65
| (A) 0.06 = (Total Current Assets 1.07b - Total Current Liabilities 755.5m) / Total Assets 4.93b |
| (B) 0.32 = Retained Earnings (Balance) 1.58b / Total Assets 4.93b |
| (C) 0.09 = EBIT TTM 427.6m / Avg Total Assets 4.68b |
| (D) 0.54 = Book Value of Equity 1.58b / Total Liabilities 2.91b |
| Total Rating: 2.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 85.08
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 2.84% = 1.42 |
| 3. FCF Margin 6.00% = 1.50 |
| 4. Debt/Equity 0.12 = 2.49 |
| 5. Debt/Ebitda 0.47 = 2.33 |
| 6. ROIC - WACC 9.24% = 11.55 |
| 7. RoE 17.15% = 1.43 |
| 8. Rev. Trend 99.05% = 4.95 |
| 9. Rev. CAGR 18.49% = 2.31 |
| 10. EPS Trend 97.09% = 2.43 |
| 11. EPS CAGR 16.69% = 1.67 |
What is the price of ENSG shares?
Over the past week, the price has changed by -4.54%, over one month by +0.03%, over three months by +8.95% and over the past year by +8.36%.
Is The Ensign a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ENSG is around 179.28 USD . This means that ENSG is currently overvalued and has a potential downside of 7.86%.
Is ENSG a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ENSG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 174.7 | 5.1% |
| Analysts Target Price | 174.7 | 5.1% |
| ValueRay Target Price | 197.3 | 18.7% |
Last update: 2025-09-05 04:41
ENSG Fundamental Data Overview
CCE Cash And Equivalents = 418.4m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 31.096
P/E Forward = 23.4192
P/S = 2.1462
P/B = 4.9339
P/EG = 1.56
Beta = 1.018
Revenue TTM = 4.61b USD
EBIT TTM = 427.6m USD
EBITDA TTM = 521.5m USD
Long Term Debt = 139.6m USD (from longTermDebt, last quarter)
Short Term Debt = 108.0m USD (from shortTermDebt, last quarter)
Debt = 247.6m USD (Calculated: Short Term 108.0m + Long Term 139.6m)
Net Debt = 1.68b USD (from netDebt column, last quarter)
Enterprise Value = 9.73b USD (9.90b + Debt 247.6m - CCE 418.4m)
Interest Coverage Ratio = 51.24 (Ebit TTM 427.6m / Interest Expense TTM 8.34m)
FCF Yield = 2.84% (FCF TTM 276.8m / Enterprise Value 9.73b)
FCF Margin = 6.00% (FCF TTM 276.8m / Revenue TTM 4.61b)
Net Margin = 6.99% (Net Income TTM 322.8m / Revenue TTM 4.61b)
Gross Margin = 18.36% ((Revenue TTM 4.61b - Cost of Revenue TTM 3.77b) / Revenue TTM)
Tobins Q-Ratio = 6.14 (Enterprise Value 9.73b / Book Value Of Equity 1.58b)
Interest Expense / Debt = 0.82% (Interest Expense 2.02m / Debt 247.6m)
Taxrate = 22.70% (87.6m / 386.1m)
NOPAT = 330.5m (EBIT 427.6m * (1 - 22.70%))
Current Ratio = 1.41 (Total Current Assets 1.07b / Total Current Liabilities 755.5m)
Debt / Equity = 0.12 (Debt 247.6m / last Quarter total Stockholder Equity 2.02b)
Debt / EBITDA = 0.47 (Net Debt 1.68b / EBITDA 521.5m)
Debt / FCF = 0.89 (Debt 247.6m / FCF TTM 276.8m)
Total Stockholder Equity = 1.88b (last 4 quarters mean)
RoA = 6.55% (Net Income 322.8m, Total Assets 4.93b )
RoE = 17.15% (Net Income TTM 322.8m / Total Stockholder Equity 1.88b)
RoCE = 21.15% (Ebit 427.6m / (Equity 1.88b + L.T.Debt 139.6m))
RoIC = 16.30% (NOPAT 330.5m / Invested Capital 2.03b)
WACC = 7.06% (E(9.90b)/V(10.15b) * Re(7.22%)) + (D(247.6m)/V(10.15b) * Rd(0.82%) * (1-Tc(0.23)))
Shares Correlation 3-Years: 93.94 | Cagr: 0.29%
Discount Rate = 7.22% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 77.38% ; FCFE base≈246.7m ; Y1≈232.4m ; Y5≈218.8m
Fair Price DCF = 67.85 (DCF Value 3.92b / Shares Outstanding 57.7m; 5y FCF grow -7.47% → 3.0% )
EPS Correlation: 97.09 | EPS CAGR: 16.69% | SUE: 0.85 | # QB: True
Revenue Correlation: 99.05 | Revenue CAGR: 18.49%
Additional Sources for ENSG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle